← Evidence map

ArticleArthritis research & therapy2019

Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial".

Annelise Madison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial". | OpenQuestion